World News
-
Eli Lilly partners with Resilience to invest US$750M in expanding KwikPen manufacturing in Ohio
The investment will upgrade Resilience’s manufacturing operations in Ohio, where the company has produced Lilly’s Mounjaro and Zepbound since the partners began working together in 2023.
-
Brenntag inks strategic global agreement with Budenheim for GMP bioprocess phosphates
The partnership combines Budenheim’s manufacturing expertise with Brenntag’s biopharma services and distribution network.
-
CEPI partners with Hilleman Laboratories to advance Bundibugyo Ebola vaccine for clinical trials
The initiative comes as scientists intensify efforts to address a major Bundibugyo ebolavirus outbreak, with cases rising rapidly in the Democratic Republic of the Congo (DRC).
-
Tel Aviv Sourasky Medical Center launches first global clinical trial of Silexion’s KRAS-targeting therapy for pancreatic cancer
The clinical trial will assess SIL204, an investigational treatment developed by Silexion using small interfering RNA (siRNA) technology.
-
Amgen’s Repatha receives positive EU opinion for expanded cardiovascular use
Repatha lowers low-density lipoprotein cholesterol (LDL-C), a key risk factor for cardiovascular disease, alongside other measures to manage cardiovascular risk.
-
Biointron launches RushData platform to accelerate AI-driven antibody discovery
RushData aims to address these bottlenecks by bringing antibody expression, binding analysis and early developability profiling into a standardised workflow.
-
Moscow expands MosMedAI platform to scale AI radiology across 75 Russian regions
Moscow opened access to its MosMedAI platform to healthcare institutions across Russia in 2024, following a decree by Russian President Vladimir Putin.
-
Newcastle Hospitals performs UK’s first adolescent spinal cord stimulation implantation
Dr Sachin Rastogi, consultant anaesthetist, and Akbar Hussain, consultant neurosurgeon and functional neurosurgeon, performed the procedure at the Royal Victoria Infirmary, part of the Newcastle Hospitals group.
-
FDA approves Otsuka’s Simtriyo as first-in-class NDSRI for ADHD treatment
The approval makes Simtriyo the first norepinephrine, dopamine, serotonin reuptake inhibitor (NDSRI) for ADHD and gives Otsuka what Jefferies analysts described as its “next major CNS launch.”
-
FDA approves Kenvue’s Tylenol with Naproxen as first OTC fixed-dose combination pain reliever
The approval provides consumers with an additional non-prescription option for managing common types of temporary pain.